Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly ( LLY 1.09%).

Representative Robert Bresnahan, Jr. sold shares of Eli Lilly and Company in April 2025, disclosing the transaction of $1,001 ...

From a fundamental standpoint, Eli Lilly presently has a market capitalization of $789 billion. Over the trailing twelve ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See why LLY is a hold.

In light of the recent options history for Eli Lilly ... In the last month, 2 experts released ratings on this stock with an average target price of $1006.0. Unusual Options Activity Detected ...

The GLP-1 obesity market will grow to approximately $90 billion by 2029, driven by significant expansion in obesity treatments, ...

Oil and related energy stocks fell, as crude prices fell to levels last seen ... Shares of AstraZeneca (AZN), Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), Johnson & Johnson (JNJ), GSK ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock is ... the prices of its Zepbound vials. A month’s supply of a ...

On this episode of Stock Movers: - Eli Lilly (LLY) shares slump while large ... economy by using its massive footprint to keep prices low and hunt for ways to take market share.

The bank rates Apple at a buy with a $250 price target. Related stories GLP-1 weight-loss drugs Analysts at Goldman Sachs believe the 21% decline in Eli Lilly stock since early March is a great ...